[This review focuses on acamprosate (Campral), which is another type of drug that may help alcoholics maintain abstinence by preventing relapse. This drug is not yet approved for use in the United States. In studies in Europe, Campral appeared to decrease the return to drinking, following a...
In several double-blind, placebo-controlled trials of up to 12 months' duration, acamprosate effectively maintained complete abstinence in detoxified alcohol-dependent patients, irrespective of disease severity or the type of psychosocial support. The drug showed better efficacy than placebo and was ...
alcoholism or alcohol withdrawal, neurological symptoms or substance abuse with substance abuse, withdrawal from drug abuse, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain To a novel combination therapy of injury or cerebral ischemic events.Selection drawing...
Acamprosate (the calcium salt of N-acetylhomotaurinate), a drug FDA-approved for relapse prevention in the treatment of alcohol dependence in adults, is a novel agent with multiple mechanisms that may be beneficial for people with FXS. There are questions regarding the neuroactive effects of ...
Three drug therapies are currently approved by the US Food and Drug Administration (FDA) for this purpose: disulfiram, naltrexone, and acamprosate. The latter was approved by the FDA in 2004.Objective:This article describes the pharmacologic properties and clinical usefulness of acamprosate for the ...
DOI: 10.1002/pmic.201700417 Pharmacoproteomics is an approach for determining molecular signaling changes correlated with drug efficacy. In article number 1700417, Germany et.al. investigated proteome changes in the brain associated with acamprosate treatment outcome using alcoholism animal model, type 1 ...
DOI: 10.1002/pmic.201700417 Pharmacoproteomics is an approach for determining molecular signaling changes correlated with drug efficacy. In article number 1700417, Germany et.al. investigated proteome changes in the brain associated with acamprosate treatment outcome using alcoholism animal model, type 1 ...
The remaining 17 studies, which included 4087 individuals, 53% of whom received active drug, were of good quality and were otherwise reasonably comparable. There was no evidence of publication bias. Continuous abstinence rates at 6 months were significantly higher in the acamprosate-treated patients ...
This open study on 614 alcohol-dependent patients from 51 centres in Belgium over 24 weeks collected data on the sociodemographic, medical and drug safety profiles and the type of psychosocial support most commonly associated with acamprosate. Psychiatric problems (34%) and gastro-intestinal ulcers (...